Amgen's new research and development facility in San Francisco. (courtesy photo) The Federal Trade Commission has put a pause on its lawsuit against Thousand Oaks-based Amgen’s acquisition of Horizon Therapeutics to allow time for the FTC to consider a settlement. If a settlement is agreed to, then this legal saga between Amgen and the FTC